ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1733-1741

  Chono, Koji ^a   Katsumata, Kiyomitsu ^a   Kontani, Toru ^a   Kobayashi, Masayuki ^a   Sudo, Kenji ^a   Yokota, Tomoyuki ^b   Konno, Kenji ^b   Shimizu, Yasuaki ^a   Suzuki, Hiroshi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Rational Drug Design Laboratories   (Japan)

Author keywords

Alphaherpesvirinae viruses; Amenamevir; Antiviral agents

Indexed keywords

ACICLOVIR; ADENOSINE TRIPHOSPHATASE; AMENAMEVIR; ANTIVIRUS AGENT; ASP 2151; DNA PRIMASE; HELICASE; UNCLASSIFIED DRUG; VALACICLOVIR; VIRUS DNA; DNA HELICASE; ENZYME INHIBITOR; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VARICELLA ZOSTER VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; CYTOMEGALOVIRUS; DISEASE MODEL; DNA SEQUENCE; DRUG EFFECTS; HERPES ZOSTER; MICROBIAL SENSITIVITY TEST; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; DNA HELICASES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HERPES ZOSTER; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; MICE; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; VIRUS REPLICATION; VIRAL PLAQUE ASSAY;

EID: 77954724450     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq198     Document Type: Article

References (36)

1. Pellet PE, Roizman B. The family Herpesviridae: a brief introduction. In: Knipe D, Howley PM, Griffin DE et al., eds, Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007; 2479-99.
2. Levin MJ, Schmader K. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. Herpes 2007; 14 Suppl 2: 45-7.
3. Roizman B, Knipe D, Whitley R. Herpes simplex viruses. In: Knipe D, Howley PM, Griffin DE et al., eds, Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2007; 2501-601.
4. De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993; 32 Suppl A: 121-32.
5. De Clercq E, Field HJ. Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147: 1-11.
6. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002; 13: 12-21.
7. Wallace MR, Bowler WA, Murray NB et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 358-63.
8. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26: 29-37.
9. Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol 2001; 21: 261-9.
10. Crute JJ, Lehman IR. Herpes simplex virus-1 helicase-primase. Physical and catalytic properties. J Biol Chem 1991; 266: 4484-8.
11. Chee MS, Bankier AT, Beck S et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990; 154: 125-69.
12. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986; 67: 1759-816.
13. Crute JJ, Grygon CA, Hargrave KD et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002; 8: 386-91.
14. Kleymann G, Fischer R, Betz UA et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8: 392-8.
15. ClinicalTrials.gov. Dose-finding study of ASP2151 in subjects with herpes zoster. http://clinicaltrials.gov/ct2/show/NCT00487682.
16. ClinicalTrials.gov. A study with ASP2151 in subjects with recurrent episodes of genital herpes. http://clinicaltrials.gov/ct2/show/NCT00486200.
17. Calder JM, Stow ND. Herpes simplex virus helicase-primase: the UL8 protein is not required for DNA-dependent ATPase and DNA helicase activities. Nucleic Acids Res 1990; 18: 3573-8.
18. Crute JJ, Bruckner RC, Dodson MS et al. Herpes simplex-1 helicase-primase. Identification of two nucleoside triphosphatase sites that promote DNA helicase action. J Biol Chem 1991; 266: 21252-6.
19. Ramirez-Aguilar KA, Low-Nam NA, Kuchta RD. Key role of template sequence for primer synthesis by the herpes simplex virus 1 helicase-primase. Biochemistry 2002; 41: 14569-79.
20. Graves-Woodward KL, Gottlieb J, Challberg MD et al. Biochemical analyses of mutations in the HSV-1 helicase-primase that alter ATP hydrolysis, DNA unwinding, and coupling between hydrolysis and unwinding. J Biol Chem 1997; 272: 4623-30.
21. Pevenstein SR, Williams RK, McChesney D et al. Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol 1999; 73: 10514-8.
22. Baba M, Shigeta S, De Clercq E. Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine on varicella-zoster virus replication in cell culture. Tohoku J Exp Med 1984; 143: 441-9.
23. Spector FC, Liang L, Giordano H et al. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 1998; 72: 6979-87.
24. Dodson MS, Lehman IR. Association of DNA helicase and primase activities with a subassembly of the herpes simplex virus 1 helicase-primase composed of the UL5 and UL52 gene products. Proc Natl Acad Sci USA 1991; 88: 1105-9.
25. Zhu LA, Weller SK. The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex. J Virol 1992; 66: 458-68.
26. Klinedinst DK, Challberg MD. Helicase-primase complex of herpes simplex virus type 1: a mutation in the UL52 subunit abolishes primase activity. J Virol 1994; 68: 3693-701.
27. De Clercq E. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 1984; 26: 155-9.
28. Boehmer PE, Lehman IR. Herpes simplex virus DNA replication. Annu Rev Biochem 1997; 66: 347-84.
29. Hodgman TC. A new superfamily of replicative proteins. Nature 1988; 333:22-3.
30. Marians KJ. Helicase structures: a new twist on DNA unwinding. Structure 1997; 5: 1129-34.
31. Gnann JW Jr, Crumpacker CS, Lalezari JP et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother 1998; 42: 1139-45.
32. Biswas S, Miguel RN, Sukla S et al. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J Gen Virol 2009; 90: 1937-42.
33. Loparev VN, Rubtcova EN, Bostik V et al. Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol 2007; 81: 12758-65.
34. Peters GA, Tyler SD, Grose C et al. A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades. J Virol 2006; 80: 9850-60.
35. Biswas S, Kleymann G, Swift M et al. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J Antimicrob Chemother 2008; 61: 1044-7.
36. Biswas S, Jennens L, Field HJ. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch Virol 2007; 152: 1489-500.